Camostat Mesilate vs Placebo (RCT)

Mild outpatients

FOREST PLOTS -2022-09-04

Studies description

Trial NCT04353284
Publication Chupp G, medRxiv (2022) (preprint)
Dates: 2020-06-01 to 2021-04-30
Funding: Mixed (Kenneth C. Griffin; the Prostate Cancer Foundation; the COVID-19 Early Treatment Fund; the Harrington Discovery Institute; institutional funds from the Department of Internal Medicine at the Yale School of Medicine, and the Yale Center for Clinical Investigation; the United State Public Health Service; Ono Pharmaceuticals provided the study drug.)
Conflict of interest: No

Trial NCT04625114
Publication Tobback E, Int J Infect Dis (2022) (published paper)
Dates: 2020-11-04 to 2021-06-30
Funding: Mixed (Ono Pharmaceuticals Co. Ltd. (Osaka, Japan) provided the study drug, camostat mesylate. Byteflies (Antwerp, Belgium) provided telemonitoring devices and technological support. No further funding was received.)
Conflict of interest: No